| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 18.515 | 24.708 | 31.963 | 34.768 | 28.039 | 23.464 | 20.822 | 24.074 | 21.894 | 17.208 |
| Total Income - EUR | 18.539 | 24.733 | 32.400 | 34.768 | 28.039 | 23.464 | 20.822 | 24.074 | 21.894 | 17.208 |
| Total Expenses - EUR | 3.732 | 3.488 | 4.469 | 7.830 | 5.982 | 7.332 | 8.945 | 8.696 | 15.184 | 15.218 |
| Gross Profit/Loss - EUR | 14.807 | 21.245 | 27.931 | 26.938 | 22.057 | 16.133 | 11.877 | 15.378 | 6.710 | 1.991 |
| Net Profit/Loss - EUR | 14.250 | 20.503 | 26.959 | 25.895 | 21.215 | 15.480 | 11.252 | 14.778 | 6.495 | 1.545 |
| Employees | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Tefas Medprevent Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 385 | 76 | 0 | 0 | 0 | 0 | 0 | 934 |
| Current Assets | 20.664 | 21.025 | 32.112 | 32.475 | 22.757 | 17.268 | 14.628 | 19.031 | 10.555 | 5.674 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 1.100 | 2.748 | 6.083 | 9.326 | 5.048 | 3.929 | 3.892 | 15.645 | 5.135 | 543 |
| Cash | 19.564 | 18.277 | 26.028 | 23.149 | 17.709 | 13.339 | 10.736 | 3.386 | 5.420 | 5.132 |
| Shareholders Funds | 20.154 | 20.556 | 27.011 | 25.946 | 21.266 | 15.571 | 11.341 | 14.867 | 6.592 | 4.281 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 83 | 81 | 81 | 81 | 80 |
| Debts | 510 | 469 | 5.485 | 6.605 | 1.491 | 1.696 | 3.287 | 4.164 | 3.962 | 2.328 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Tefas Medprevent Srl